Seroatlas · Human Serome Atlas

VCPKMT

Protein N-lysine methyltransferase METTL21D

Also known as: C14orf138, METTL21D, MT21D_HUMAN, VCP-KMT

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9H867
Gene: VCPKMT
Ensembl: ENSG00000100483
Chromosome: 14
Canonical length: 229 aa
Protein class: Predicted intracellular proteins
Subcellular location: Cytosol

OverviewNCBI Gene

Enables ATPase binding activity and protein-lysine N-methyltransferase activity. Involved in negative regulation of ATP-dependent activity and peptidyl-lysine trimethylation. Located in cytosol. Part of protein-containing complex. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

229 residues, UniProt reviewed canonical sequence.

>Q9H867|VCPKMT
     1  MADTLESSLE DPLRSFVRVL EKRDGTVLRL QQYSSGGVGC VVWDAAIVLS KYLETPEFSG
    61  DGAHALSRRS VLELGSGTGA VGLMAATLGA DVVVTDLEEL QDLLKMNINM NKHLVTGSVQ
   121  AKVLKWGEEI EGFPSPPDFI LMADCIYYEE SLEPLLKTLK DISGFETCII CCYEQRTMGK
   181  NPEIEKKYFE LLQLDFDFEK IPLEKHDEEY RSEDIHIIYI RKKKSKFPS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against VCPKMT can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.29
Highest tissue expression: 5.6 nTPM

Expression across tissuesHPA

Tissue

cerebellum: 5.6 nTPM
cerebral cortex: 5.5 nTPM
bone marrow: 4.8 nTPM
spleen: 4.3 nTPM
thymus: 4.3 nTPM
esophagus: 4.2 nTPM

Single-cell type

neutrophils: 96 nCPM
plasma cells: 52 nCPM
neutrophil progenitors: 50 nCPM
b-cells: 49 nCPM
early spermatids: 48 nCPM
suprabasal keratinocytes: 45 nCPM

Immune cell

memory B-cell: 27 nTPM
naive B-cell: 22 nTPM
naive CD8 T-cell: 12 nTPM
basophil: 12 nTPM
NK-cell: 12 nTPM
memory CD8 T-cell: 12 nTPM

Brain region

choroid plexus: 6.7 nTPM
cerebral cortex: 5.6 nTPM
white matter: 5.4 nTPM
cerebellum: 5.2 nTPM
hippocampal formation: 5.2 nTPM
thalamus: 4.8 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.84
gnomAD pLI: 0
gnomAD missense Z: -1.61
DepMap mean gene effect: -0.21
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of VCPKMT in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads VCPKMT as an antibody target. Whether an autoantibody or antibody against VCPKMT could matter depends on whether native VCPKMT is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

VCPKMT is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label VCPKMT as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...